Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 594

1.

[A New Twist on the Administration of Naldemedine for Opioid-Induced Constipation in an Outpatient].

Shikada Y, Emi Y, Kometani T, Ochiai T, Fujii M, Noda Y, Kajiwara M, Ikeda M, Asonuma S, Mori M.

Gan To Kagaku Ryoho. 2018 Jul;45(7):1075-1079. Japanese.

PMID:
30042276
2.

Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report.

Muller G, Grieshaber R, Talley JF, Riepl M, Fellows D.

Int J Pharm Compd. 2018 Jul-Aug;22(4):270-278.

PMID:
30021181
3.

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.

Candy B, Jones L, Vickerstaff V, Larkin PJ, Stone P.

Cochrane Database Syst Rev. 2018 Jun 5;6:CD006332. doi: 10.1002/14651858.CD006332.pub3. Review.

PMID:
29869799
4.

Low dose naltrexone for induction of remission in Crohn's disease.

Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N.

Cochrane Database Syst Rev. 2018 Apr 1;4:CD010410. doi: 10.1002/14651858.CD010410.pub3. Review.

PMID:
29607497
5.

Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.

Setnik B, Schoedel K, Bartlett C, Dick C, Hakim N, Geoffroy P.

J Opioid Manag. 2017 Nov/Dec;13(6):449-464. doi: 10.5055/jom.2017.0421.

PMID:
29308591
6.
7.

Current pharmacotherapies for obesity: A practical perspective.

Golden A.

J Am Assoc Nurse Pract. 2017 Oct;29(S1):S43-S52. doi: 10.1002/2327-6924.12519. Review.

PMID:
29024552
8.

Opioid receptor antagonists in the treatment of pathological gambling.

Coppola M, Mondola R.

J Opioid Manag. 2017 Jul/Aug;13(4):205-206. doi: 10.5055/jom.2017.0388. No abstract available.

PMID:
28983886
9.

Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials.

Johansen KGV, Tarp S, Astrup A, Lund H, Pagsberg AK, Christensen R.

PLoS One. 2017 Aug 29;12(8):e0183821. doi: 10.1371/journal.pone.0183821. eCollection 2017. Review.

10.

Low-Dose Naltrexone Treatment of Familial Benign Pemphigus (Hailey-Hailey Disease).

Ibrahim O, Hogan SR, Vij A, Fernandez AP.

JAMA Dermatol. 2017 Oct 1;153(10):1015-1017. doi: 10.1001/jamadermatol.2017.2445.

11.

Perioperative Pain Management of a Patient Taking Naltrexone HCl/Bupropion HCl (Contrave): A Case Report.

Ninh A, Kim S, Goldberg A.

A A Case Rep. 2017 Oct 15;9(8):224-226. doi: 10.1213/XAA.0000000000000573.

PMID:
28604472
12.

Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.

Hale M, Wild J, Reddy J, Yamada T, Arjona Ferreira JC.

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):555-564. doi: 10.1016/S2468-1253(17)30105-X. Epub 2017 May 30.

PMID:
28576452
13.

Naloxegol, an opioid antagonist with reduced CNS penetration: Mode-of-action and human relevance for rat testicular tumours.

Andersson H, Mitchard T, Johnson N, Floettmann E.

Toxicol Appl Pharmacol. 2017 Aug 15;329:85-95. doi: 10.1016/j.taap.2017.05.032. Epub 2017 May 26.

PMID:
28554659
15.

Naldemedine effective in treating opioid-induced constipation.

Brower V.

Lancet Oncol. 2017 Jun;18(6):e306. doi: 10.1016/S1470-2045(17)30320-0. Epub 2017 May 5. No abstract available.

PMID:
28483411
16.

A Comparison of Sexual Side Effects of Antidepressants With and Without Naltrexone.

Thapa M, Petrakis I, Ralevski E.

J Dual Diagn. 2017 Jul-Sep;13(3):230-235. doi: 10.1080/15504263.2017.1326650. Epub 2017 May 8.

PMID:
28481169
17.

Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.

Katakami N, Oda K, Tauchi K, Nakata K, Shinozaki K, Yokota T, Suzuki Y, Narabayashi M, Boku N.

J Clin Oncol. 2017 Jun 10;35(17):1921-1928. doi: 10.1200/JCO.2016.70.8453. Epub 2017 Apr 26.

PMID:
28445097
18.

Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians.

Franchitto N, Jullian B, Salles J, Pelissier F, Rolland B.

Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):669-677. doi: 10.1080/17425255.2017.1312340. Epub 2017 Apr 3. Review.

PMID:
28343423
19.

Obesity Epidemic: Pharmaceutical Weight Loss.

Curry SA.

R I Med J (2013). 2017 Mar 1;100(2):18-20.

PMID:
28246654
20.

Acute Generalized Erythrodermic Pustular Psoriasis Associated with Bupropion/Naltrexone (Contrave®).

Singh PA, Cassel KP, Moscati RM, Eckersley D.

J Emerg Med. 2017 Apr;52(4):e111-e113. doi: 10.1016/j.jemermed.2016.11.034. Epub 2017 Jan 24.

PMID:
28130024

Supplemental Content

Loading ...
Support Center